Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Endocrinol., 09 September 2025

Sec. Bone Research

Volume 16 - 2025 | https://doi.org/10.3389/fendo.2025.1690095

Correction: Mechanism of action of curculigoside ameliorating osteoporosis: an analysis based on network pharmacology and experimental validation

This article is a correction to:

  1. Mechanism of action of curculigoside ameliorating osteoporosis: an analysis based on network pharmacology and experimental validation

    1. Read original article
Chuanfu Wei,&#x;Chuanfu Wei1,2‡Wenhuan Zhang&#x;Wenhuan Zhang2‡Chunbiao LouChunbiao Lou1Nianhu Li*&#x;Nianhu Li2*†Hui Cao*&#x;Hui Cao1*†
  • 1The First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, China
  • 2Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China

A Correction on
Mechanism of action of curculigoside ameliorating osteoporosis: an analysis based on network pharmacology and experimental validation

By Wei C, Zhang W, Lou C, Li N and Cao H (2025) Front. Endocrinol. 16:1549471. doi: 10.3389/fendo.2025.1549471

Affiliation “1 The First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, China” and was erroneously given as “1 Shandong University of Chinese Medicine, Jinan, China”.

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: curculigoside, osteoporosis, network pharmacology, molecular docking, micro CT technology

Citation: Wei C, Zhang W, Lou C, Li N and Cao H (2025) Correction: Mechanism of action of curculigoside ameliorating osteoporosis: an analysis based on network pharmacology and experimental validation. Front. Endocrinol. 16:1690095. doi: 10.3389/fendo.2025.1690095

Received: 21 August 2025; Accepted: 29 August 2025;
Published: 09 September 2025.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2025 Wei, Zhang, Lou, Li and Cao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Hui Cao, Y2FvaHVpNjNAMTYzLmNvbQ==; Nianhu Li, dGlnZXJsZWUwNzNAMTI2LmNvbQ==

†These authors have contributed equally to this work

‡These authors share first authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.